[go: up one dir, main page]

WO2002062985A1 - Levure faisant preuve d'un activite immunoregulatrice cellulaire nk, son procede de preparation et ses applications - Google Patents

Levure faisant preuve d'un activite immunoregulatrice cellulaire nk, son procede de preparation et ses applications Download PDF

Info

Publication number
WO2002062985A1
WO2002062985A1 PCT/CN2001/000118 CN0100118W WO02062985A1 WO 2002062985 A1 WO2002062985 A1 WO 2002062985A1 CN 0100118 W CN0100118 W CN 0100118W WO 02062985 A1 WO02062985 A1 WO 02062985A1
Authority
WO
WIPO (PCT)
Prior art keywords
yeast
genes
cell
specific
regulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2001/000118
Other languages
English (en)
Chinese (zh)
Inventor
Kamfu Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SIX FOREST BIO-SCIENCE INSTITUTE Ltd
Original Assignee
SIX FOREST BIO-SCIENCE INSTITUTE Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SIX FOREST BIO-SCIENCE INSTITUTE Ltd filed Critical SIX FOREST BIO-SCIENCE INSTITUTE Ltd
Priority to PCT/CN2001/000118 priority Critical patent/WO2002062985A1/fr
Publication of WO2002062985A1 publication Critical patent/WO2002062985A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention porte sur un procédé permettant d'activer des gènes récessifs de levure ordinaire faisant appel à une information relative à des ondes électromagnétiques de vie simulées afin de transformer la levure ordinaire en levure spécifique, les protéines spécifiques (enzymes) exprimées par la levure spécifique présentent les fonctions d'activation, de régulation, de correction des gènes immunitaires des lymphocytes B, des gènes immunitaires des lymphocytes T, des gènes immunitaires des lymphocytes K et des gènes allèles des lymphocytes NK à faible compétence immunologique. La levure spécifique se présente sous forme de préparation biologique afin de réguler les gènes immunitaires du corps dans la reconstruction de la fonction immunitaire du corps et dans le rétablissement d'un patient ayant souffert diverses maladies. La préparation biologique de cette invention est indiquée dans la prévention et le traitement de différentes tumeurs, de l'urémie, de l'hépatite, de la presbyophrénie, de diverses maladies gastro-intestinales, du diabète, des troubles du système nerveux et analogues. Cette préparation est très efficace et n'entraîne pas d'effets toxiques ou secondaires
PCT/CN2001/000118 2001-02-08 2001-02-08 Levure faisant preuve d'un activite immunoregulatrice cellulaire nk, son procede de preparation et ses applications Ceased WO2002062985A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2001/000118 WO2002062985A1 (fr) 2001-02-08 2001-02-08 Levure faisant preuve d'un activite immunoregulatrice cellulaire nk, son procede de preparation et ses applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2001/000118 WO2002062985A1 (fr) 2001-02-08 2001-02-08 Levure faisant preuve d'un activite immunoregulatrice cellulaire nk, son procede de preparation et ses applications

Publications (1)

Publication Number Publication Date
WO2002062985A1 true WO2002062985A1 (fr) 2002-08-15

Family

ID=4574772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2001/000118 Ceased WO2002062985A1 (fr) 2001-02-08 2001-02-08 Levure faisant preuve d'un activite immunoregulatrice cellulaire nk, son procede de preparation et ses applications

Country Status (1)

Country Link
WO (1) WO2002062985A1 (fr)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1375652A3 (fr) * 2002-06-28 2004-01-07 Ultra Biotech Limited Composition orale pour des sujets infectés par le VIH
EP1375651A3 (fr) * 2002-06-28 2004-01-07 Ultra Biotech Limited Composition orale pour l'activation et la prolifération des globules blancs
US6913913B2 (en) 2003-11-18 2005-07-05 Ultra Biotech Limited Methods and compositions for treating renal failure
US6913914B2 (en) 2003-11-18 2005-07-05 Ultra Biotech Limited Methods and compositions for treating hepatitis B
US6964864B2 (en) 2003-11-18 2005-11-15 Ultra Biotech Limited Methods and compositions for treating gastritis
US6977168B2 (en) 2003-11-18 2005-12-20 Ultra Biotech Limited Methods and compositions for treating nephrotic syndrome
US6979562B2 (en) 2003-11-18 2005-12-27 Ultra Biotech Limited Methods and compositions for treating gastroparesis
US6984508B2 (en) 2003-06-11 2006-01-10 Ultra Biotech Limited Biological compositions and methods for treatment of cervical cancer
US6984507B2 (en) 2003-06-11 2006-01-10 Ultra Biotech Limited Biological compositions and methods for treatment of lung cancer
US6987012B2 (en) 2003-06-11 2006-01-17 Ultra Biotech Limited Biological compositions and methods for treatment of colorectal cancer
US6989253B2 (en) 2003-06-11 2006-01-24 Ultra Biotech Limited Biological compositions and methods for treatment of testicular cancer
US7078202B2 (en) 2003-11-18 2006-07-18 Ultra Biotech Limited Methods and compositions for treating vascular dementia
US7201906B2 (en) 2003-06-11 2007-04-10 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7204987B2 (en) 2003-06-11 2007-04-17 Ultra Biotech Limited Biological compositions and methods for treatment of prostate cancer
US7204988B2 (en) 2003-06-11 2007-04-17 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7204986B2 (en) 2003-06-11 2007-04-17 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7208158B2 (en) 2003-06-11 2007-04-24 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7214377B2 (en) 2003-06-11 2007-05-08 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7220416B2 (en) 2003-06-11 2007-05-22 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223403B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223400B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223405B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepareompositions comprising yeast treated with electromagnetic energy
US7223402B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223401B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223404B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7226600B2 (en) 2003-06-11 2007-06-05 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7259001B2 (en) 2003-11-18 2007-08-21 Ultra Biotech Limited Methods and compositions for treating male sexual dysfunction
US7297522B2 (en) 2003-11-18 2007-11-20 Ultra Biotech Limited Methods and compositions for treating epilepsy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8402388A (nl) * 1983-08-01 1985-03-01 Shigezo Udaka Geneesmiddel spf-100 en werkwijze voor de bereiding hiervan.
SU1174475A1 (ru) * 1984-02-10 1985-08-23 Предприятие П/Я А-1067 Способ обработки пивных дрожжей
SU1592328A1 (ru) * 1988-05-16 1990-09-15 Ki T I Pishchevoj Promy Cпocoб aktиbaции xлeбoпekaphыx дpoжжeй
EP0615757A1 (fr) * 1993-03-18 1994-09-21 Georges Serge Grimberg Composition thérapeutique nouvelle ayant un effet immunostimulant

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8402388A (nl) * 1983-08-01 1985-03-01 Shigezo Udaka Geneesmiddel spf-100 en werkwijze voor de bereiding hiervan.
SU1174475A1 (ru) * 1984-02-10 1985-08-23 Предприятие П/Я А-1067 Способ обработки пивных дрожжей
SU1592328A1 (ru) * 1988-05-16 1990-09-15 Ki T I Pishchevoj Promy Cпocoб aktиbaции xлeбoпekaphыx дpoжжeй
EP0615757A1 (fr) * 1993-03-18 1994-09-21 Georges Serge Grimberg Composition thérapeutique nouvelle ayant un effet immunostimulant

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1375652A3 (fr) * 2002-06-28 2004-01-07 Ultra Biotech Limited Composition orale pour des sujets infectés par le VIH
EP1375651A3 (fr) * 2002-06-28 2004-01-07 Ultra Biotech Limited Composition orale pour l'activation et la prolifération des globules blancs
US7204987B2 (en) 2003-06-11 2007-04-17 Ultra Biotech Limited Biological compositions and methods for treatment of prostate cancer
US7220416B2 (en) 2003-06-11 2007-05-22 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7226600B2 (en) 2003-06-11 2007-06-05 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223404B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223401B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US6984508B2 (en) 2003-06-11 2006-01-10 Ultra Biotech Limited Biological compositions and methods for treatment of cervical cancer
US6984507B2 (en) 2003-06-11 2006-01-10 Ultra Biotech Limited Biological compositions and methods for treatment of lung cancer
US6987012B2 (en) 2003-06-11 2006-01-17 Ultra Biotech Limited Biological compositions and methods for treatment of colorectal cancer
US6989253B2 (en) 2003-06-11 2006-01-24 Ultra Biotech Limited Biological compositions and methods for treatment of testicular cancer
US7223402B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7163813B2 (en) 2003-06-11 2007-01-16 Ultra Biotech Limited Biological compositions and methods for treatment of colorectal cancer
US7172889B2 (en) 2003-06-11 2007-02-06 Ultra Biotech Limited Biological compositions and methods for treatment of cervical cancer
US7172888B2 (en) 2003-06-11 2007-02-06 Ultra Biotech Limited Biological compositions and methods for treatment of lung cancer
US7201906B2 (en) 2003-06-11 2007-04-10 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223405B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepareompositions comprising yeast treated with electromagnetic energy
US7204986B2 (en) 2003-06-11 2007-04-17 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223400B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7208158B2 (en) 2003-06-11 2007-04-24 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223403B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7214377B2 (en) 2003-06-11 2007-05-08 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7204988B2 (en) 2003-06-11 2007-04-17 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7208159B2 (en) 2003-11-18 2007-04-24 Ultra Biotech Limited Methods and compositions for treating gastroparesis
US6913913B2 (en) 2003-11-18 2005-07-05 Ultra Biotech Limited Methods and compositions for treating renal failure
US6913914B2 (en) 2003-11-18 2005-07-05 Ultra Biotech Limited Methods and compositions for treating hepatitis B
US7078202B2 (en) 2003-11-18 2006-07-18 Ultra Biotech Limited Methods and compositions for treating vascular dementia
US6979562B2 (en) 2003-11-18 2005-12-27 Ultra Biotech Limited Methods and compositions for treating gastroparesis
US6977168B2 (en) 2003-11-18 2005-12-20 Ultra Biotech Limited Methods and compositions for treating nephrotic syndrome
US6964864B2 (en) 2003-11-18 2005-11-15 Ultra Biotech Limited Methods and compositions for treating gastritis
US7259001B2 (en) 2003-11-18 2007-08-21 Ultra Biotech Limited Methods and compositions for treating male sexual dysfunction
US7297522B2 (en) 2003-11-18 2007-11-20 Ultra Biotech Limited Methods and compositions for treating epilepsy

Similar Documents

Publication Publication Date Title
WO2002062983A1 (fr) Levure faisant preuve d'une activite immunoregulatrice des lymphocytes t, son procede de preparation et ses applications
WO2002062985A1 (fr) Levure faisant preuve d'un activite immunoregulatrice cellulaire nk, son procede de preparation et ses applications
WO2002062981A1 (fr) Immunoregulateur humain de levure et son procede de preparation
WO2002062984A1 (fr) Levure faisant preuve d'une activite immunoregulatrice du lymphocyte k, son procede de production et ses applications
WO2002062982A1 (fr) Levure faisant preuve d'une activite immunoregulatrice des lymphocytes b, son procede de preparation et ses applications
Guan et al. Aflatoxin B1 degradation by Stenotrophomonas maltophilia and other microbes selected using coumarin medium
EP1375651A3 (fr) Composition orale pour l'activation et la prolifération des globules blancs
WO2006067122A3 (fr) Molecules de liaison capables de neutraliser le virus du nil occidental et utilisations correspondantes
WO2001092308A3 (fr) Polypeptides a noeud de cystines: molecules 'cloaked-2' et leurs utilisations
WO1998009990A8 (fr) Antigenes fongiques et processus de fabrication
WO2003087115A3 (fr) Composes oligomeres a groupes phosphate modifies
WO2007099348A3 (fr) Peptide et ses utilisations
Cappello et al. Identification and selection of prospective probiotics for enhancing gastrointestinal digestion: Application in pharmaceutical preparations and dietary supplements
CN106011118B (zh) 一种Fe3+依赖型食品级酸性脲酶及其在黄酒中的应用
EP2116616A3 (fr) Gènes exprimés differentiellement dans des cellules T activées et leurs utilisations
TW200734638A (en) Method for the diagnosis of thromboembolic and coronary heart diseases
Xiao et al. Identification, Nutrient Composition, and Evaluation of a Wild Pleurotus citrinopileatus Strain (X21156) from Tibet for Antioxidant and Cytotoxic Activities
WO2001064870A3 (fr) Proteine cycline g1 mutee
WO2003006630A3 (fr) Preparations fantomes exemptes d'acides nucleiques
WO2002074921A3 (fr) Methodes d'isolement de proteines exprimees au moyen de cellules dendritiques
WO2005023979A3 (fr) Molecules d'acide nucleique de s. mansoni isolees et utilisations associees
WO1995034649A3 (fr) Gene 1 de la polykystose renale et utilisations dudit gene
WO2001085785A3 (fr) Proteine d'interaction avec le domaine ph
WO2004074440A3 (fr) Preparation d'organismes a croissance plus rapide et/ou a rendement plus eleve
WO2002086067A3 (fr) Proteines mycobacteriennes a voie de sulfatation et leurs procedes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP